EGFR and neoplasm: For safety analysis, EGFR drug-related skin toxicities (RR 24.12, 95% CI 13.11–44.36; p < 0.00001) and hypomagnesaemia (RR 13.49, 95% CI 3.20–56.81; p = 0.0004) were more associated with anti-EGFR combination regimen.